Antigens for CD4 and CD8 T cells in tuberculosis

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 7, 2014, Pages

  Lindestam Arlehamn, Cecilia S ^a   Lewinsohn, David ^b,c   Sette, Alessandro ^a   Lewinsohn, Deborah ^b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD8 ANTIGEN; EPITOPE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; PROTEIN; BACTERIAL ANTIGEN; HLA D ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; GENETIC ASSOCIATION; HOST RESISTANCE; HUMAN; LYMPHOCYTE FUNCTION; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; PROTEIN TARGETING; TUBERCULOSIS; BACTERIAL GENOME; CELLULAR IMMUNITY; IMMUNOLOGY; PHYSIOLOGY;

MYCOBACTERIUM TUBERCULOSIS;

ANTIGENS, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; GENOME, BACTERIAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-D ANTIGENS; HUMANS; IMMUNITY, CELLULAR; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84907581808     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a018465     Document Type: Article

References (156)

1. Aagaard C, Brock I, Olsen A, Ottenhoff THM, Weldingh K, Andersen P. 2004. Mapping immune reactivity toward Rv2653 and Rv2654: Two novel low-molecular-mass antigens found specifically in the Mycobacterium tuberculosis complex. J Infect Dis 189: 812-819.
2. Abdallah AM, Verboom T, Weerdenburg EM, Gey van Pittius NC, Mahasha PW, Jimenez C, Parra M, Cadieux N, Brennan MJ, Appelmelk BJ, et al. 2009. PPE and PE_PGRS proteins ofMycobacterium marinum are transported via the type VII secretion system ESX-5. Mol Microbiol 73: 329-340.
3. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gat-torno M, Lanzavecchia A, Sallusto F, Napolitani G. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8: 639-646.
4. Akhter Y, Ehebauer MT, Mukhopadhyay S, Hasnain SE. 2011. The PE/PPE multigene family codes for virulence factors and are a possible source of mycobacterial antigenic variation: Perhaps more? Biochimie 94: 110-116.
5. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A, et al. 1994. Development of high potency universal DR-re-stricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1: 751-761.
6. Andersen P. 1994. The T cell response to secreted antigens of Mycobacterium tuberculosis. Immunobiology 191:537-547.
7. Andersen P, Doherty TM. 2005. TB subunit vaccines—Putting the pieces together. Microbes Infect 7: 911-921.
8. Andersen P, Askgaard D, Ljungqvist L, Bennedsen J, Heron I. 1991. Proteins released from Mycobacterium tuberculosis during growth. InfectImmun 59: 1905-1910.
9. Arend SM, Geluk A, van Meijgaarden KE, van Dissel JT, Theisen M, Andersen P, Ottenhoff THM. 2000. Antigenic equivalence ofhuman T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect Immun 68: 3314-3321.
10. Assarsson E, Bui H-H, Sidney J, Zhang Q, Glenn J, Oseroff C, Mbawuike IN, Alexander J, Newman MJ, Grey H, et al. 2008. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol 82: 12241-12251.
11. Axelsson-Robertson R, Weichold F, Sizemore D, Wulf M, Skeiky YA, Sadoff J, Maeurer MJ. 2010. Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8 T-cell responses. Immunology 129: 496-505.
12. Axelsson-Robertson R, Ahmed RK, Weichold FF, Ehlers MM, Kock MM, Sizemore D, Sadoff J, Maeurer M. 2011. Human leukocyte antigens A* 3001 and A* 3002 show distinct peptide-binding patterns of the Mycobac-terium tuberculosis protein TB10.4: Consequences for immune recognition. Clin Vaccine Immunol 18: 125-134.
13. Axelsson-Robertson R, Magalhaes I, Parida SK, Zumla A, Maeurer M. 2012. The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition. J Infect Dis 205: S301-S315.
14. Axelsson-Robertson R, Loxton AG, Walzl G, Ehlers MM, Kock MM, Zumla A, Maeurer M. 2013. A broad profile of co-dominant epitopes shapes the peripheral Myco-bacterium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis. PLoS ONE 8: e58309.
15. Baena A, Porcelli SA. 2009. Evasion and subversion of antigen presentation by Mycobacterium tuberculosis. Tissue Antigens 74: 189-204.
16. Barnes PF, Bloch AB, Davidson PT, Snider DE Jr. 1991. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 324: 1644-1650.
17. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845-855.
18. Beatty WL, Russell DG. 2000. Identification of myco-bacterial surface proteins released into subcellular compartments of infected macrophages. Infect Immun 68: 6997-7002.
19. Beatty WL, Rhoades ER, Ullrich HJ, Chatterjee D, Heuser JE, Russell DG. 2000. Trafficking and release of mycobacterial lipids from infected macrophages. Traffic 1: 235-247.
20. Beatty WL, Ullrich HJ, Russell DG. 2001. Mycobacterial surface moieties are released from infected macrophages by a constitutive exocytic event. Eur JCell Biol 80: 31-40.
21. Beckman EM, Melian A, Behar SM, Sieling PA, Chatterjee D, Furlong ST, Matsumoto R, Rosat JP, Modlin RL, Porcelli SA. 1996. CD1c restricts responses of mycobacteria-specific T cells. Evidence for antigen presentation by a second member of the human CD1 family. J Immunol 157: 2795-2803.
22. Behar SM. 2013. Antigen-specific CD8+ T cells and protective immunity to tuberculosis. Adv Exp Med Biol 783: 141-163.
23. Behar SM, Divangahi M, Remold HG. 2010. Evasion of innate immunity by Mycobacterium tuberculosis: Is death an exit strategy? Nat Rev Microbiol 8: 668-674.
24. Behr M, Wilson M, Gill W, Salamon H, Spchoolnik G, Rane S, Small P. 1999. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284: 1520-1523.
25. Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler RN, et al. 2008. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol 181: 7948-7957.
26. Black GF, Thiel BA, Ota MO, Parida SK, Adegbola R, Boom WH, Dockrell HM, Franken KL, Friggen AH, Hill PC, et al. 2009. Immunogenicity of novel DosR regulon-encod-ed candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol 16: 1203-1212.
27. Blythe M, Zhang Q, Vaughan K, de Castro R, Salimi N, Bui H-H, Lewinsohn D, Ernst J, Peters B, Sette A. 2007. An analysis of the epitope knowledge related to Mycobacte-ria. Immunome Res 3: 10.
28. Boesen H, Jensen B, Wilcke T, Andersen P. 1995. Human T-cell responses to secreted antigen fractions ofMycobac-terium tuberculosis. Infect Immun 63: 1491-1497.
29. Brock I, Weldingh K, Leyten EMS, Arend SM, Ravn P, Andersen P. 2004. Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. JClin Microbiol 42: 2379-2387.
30. Caccamo N, Milano S, Di Sano C, Cigna D, Ivanyi J, Krensky AM, Dieli F, Salerno A. 2002. Identification of epitopes of Mycobacterium tuberculosis 16-kDa protein recognized by human leukocyte antigen-A*0201 CD8+ T lymphocytes. J Infect Dis 186: 991-998.
31. Caccamo N, Guggino G, Meraviglia S, Gelsomino G, Di Carlo P, Titone L, Bocchino M, Galati D, Matarese A, Nouta J, et al. 2009. Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS ONE 4: e5528.
32. Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, Flynn JL. 1999. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-g, yet succumb to tuberculosis. J Immunol 162: 5407-5416.
33. Chaitra MG, Shaila MS, Chandra NR, Nayak R. 2008. HLA-A* 0201-restricted cytotoxic T-cell epitopes in three PE/PPE family proteins of Mycobacterium tuberculosis. Scand J Immunol 67: 411-417.
34. Chegou N, Black G, Loxton A, Stanley K, Essone P, Klein M, Parida S, Kaufmann S, Doherty TM, Friggen A, et al. 2012. Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infect Dis 12: 10.
35. Cockle PJ, Gordon SV, Lalvani A, Buddle BM, Hewinson RG, Vordermeier HM. 2002. Identification of novel My-cobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. Infect Immun 70: 6996-7003.
36. Cole S, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon S, Eiglmeier K, Gas S, Barry C, et al. 1998. Deciphering the biologyofMycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
37. Coler RN, Dillon DC, Skeiky YAW, Kahn M, Orme IM, Lobet Y, Reed SG, Alderson MR. 2009. Identification of Myco-bacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning. Vaccine 27: 223-233.
38. Commandeur S, Lin MY, van Meijgaarden KE, Friggen AH, Franken KL, Drijfhout JW, Korsvold GE, Oftung F, Geluk A, Ottenhoff TH. 2011a. Double- and monofunctional CD4+ and CD8+ T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. Eur J Immunol 41: 2925-2936.
39. Commandeur S, van Meijgaarden KE, Lin MY, Franken KLMC, Friggen AH, Drijfhout JW, Oftung F, Korsvold GE, Geluk A, Ottenhoff THM. 2011b. Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation promoting factors in long-term latently infected individuals. Clin Vaccine Immunol 41:2925-2936.
40. Commandeur S, van Meijgaarden KE, Prins C, Pichugin AV, Dijkman K, van den Eeden SJ, Friggen AH, Franken KL, Dolganov G, Kramnik I, et al. 2013. An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection. J Immunol 190: 1659-1671.
41. Cooper AM. 2009. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27: 393-422.
42. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. 1993. Disseminated tuberculosis in interferon g gene-disrupted mice. J Exp Med 178: 2243-2247.
43. Covert BA, Spencer JS, Orme IM, Belisle JT. 2001. The application of proteomics in defining the T cell antigens of Mycobacterium tuberculosis. Proteomics 1: 574-586.
44. de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, Kabel PJ, Draaisma JM, van Dissel JT, Kroon FP, et al. 1998. Severe mycobacterial and salmonella infections in interleukin-12 receptor-deficient patients. Science 280: 1435-1438.
45. Deenadayalan A, Heaslip D, Rajendiran AA, Velayudham BV, Frederick S, Yang HL, Dobos K, Belisle JT, Raja A. 2010. Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients. Mol Cell Pro-teomics 9: 538-549.
46. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. 2010. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol 11: 751-758.
47. Dong Y, Demaria S, Sun X, Santori FR, Jesdale BM, De Groot AS, Rom WN, Bushkin Y. 2004. HLA-A2-restricted CD8+-cytotoxic-T-cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, ala-nine dehydrogenase, and glutamine synthetase. Infect Immun 72: 2412-2415.
48. Doolan DL, Southwood S, Chesnut R, Appella E, Gomez E, Richards A, Higashimoto YI, Maewal A, Sidney J, Gram-zinski RA, et al. 2000. HLA-DR-promiscuous T cell epi-topes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLAClass II alleles. JImmunol 165: 1123-1137.
49. Dorman SE, Holland SM. 2000. Interferon-g and interleu-kin-12 pathway defects and human disease. Cytokine Growth Factor Rev 11: 321-333.
50. Florczyk MA, McCue LA, Stack RF, Hauer CR, McDonough KA. 2001. Identification and characterization of myco-bacterial proteins differentiallyexpressed under standing and shaking culture conditions, including Rv2623 from a novel class of putative ATP-binding proteins. Infect Immun 69: 5777-5785.
51. Flynn JL. 2006. Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect 8: 1179-1188.
52. Flynn JL, Chan J. 2001. Immunology of tuberculosis. Annu Rev Immunol 19: 93-129.
53. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. 1992. Major histocompatibilitycomplexclass I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci 89: 12013-12017.
54. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. 1993. An essential role for interferon g in resistance to Mycobacterium tuberculosis infection. JExp Med 178: 2249-2254.
55. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. 2010. Multidrug-resis-tant and extensively drug-resistant tuberculosis: A threat to global control oftuberculosis. Lancet 375: 1830-1843.
56. Geyvan Pittius N, Gamieldien J, Hide W, Brown G, Siezen R, Beyers A. 2001. The ESAT-6 gene cluster of Mycobac-terium tuberculosis and other high G + C Gram-positive bacteria. Genome Biol 2: research0044.0041 -re- search0044.0018.
57. Gey van Pittius N, Sampson S, Lee H, Kim Y, van Helden P, Warren R. 2006. Evolution and expansion of the Myco-bacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6(esx) gene cluster regions. BMC Evol Biol 6: 95.
58. Gideon HP, Wilkinson KA, Rustad TR, Oni T, Guio H, Ko- zak RA, Sherman DR, Meintjes G, Behr MA, Vordermeier HM, et al. 2010. Hypoxia induces an immunodominant target of tuberculosis specific T cells absent from common BCG vaccines. PLoS Pathog 6: e1001237.
59. Gold MC, Lewinsohn DM. 2013. Co-dependents: MR1- restricted MAIT cells and their antimicrobial function. Nat Rev Microbiol 11: 14-19.
60. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, Winata E, Swarbrick GM, Chua WJ, Yu YY, et al. 2010. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 8: e1000407.
61. Gosselin A, Monteiro P, Chomont N, Diaz-Griffero F, Said EA, Fonseca S, Wacleche V, El-Far M, Boulassel MR, Routy JP, et al. 2010. Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol 184: 1604-1616.
62. Grotzke JE, Lewinsohn DM. 2005. Role of CD8+ T lymphocytes in control of Mycobacterium tuberculosis infection. Microbes Infect 7: 776-788.
63. Grotzke JE, Harriff MJ, Siler AC, Nolt D, Delepine J, Lew- insohn DA, Lewinsohn DM. 2009. The Mycobacterium tuberculosis phagosome is a HLA-I processing competent organelle. PLoS Pathog 5: e1000374.
64. Grotzke JE, Siler AC, Lewinsohn DA, Lewinsohn DM. 2010. Secreted immunodominant Mycobacterium tuberculosis antigens are processed by the cytosolic pathway. J Immunol 185: 4336-4343.
65. Hammond AS, Klein MR, Corrah T, Fox A, Jaye A, McAdam KP, Brookes RH. 2005. Mycobacterium tuberculosis genome-wide screen exposes multiple CD8+ T cell epitopes. Clin Exp Immunol 140: 109-116.
66. Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. 1996. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobac-terium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 64: 16-22.
67. Heinzel AS, Grotzke JE, Lines RA, Lewinsohn DA, McNabb AL, Streblow DN, Braud VM, Grieser HJ, Belisle JT, Lew-insohn DM. 2002. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells. J Exp Med 196: 1473-1481.
68. Honer zu Bentrup K, Russell DG. 2001. Mycobacterial persistence: Adaptation to a changing environment. Trends Microbiol 9: 597-605.
69. Hopewell PC. 1992. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis. Clin Infect Dis 15: 540-547.
70. Horwitz MA, Lee BW, Dillon BJ, Harth G. 1995. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci 92: 1530-1534.
71. Hubbard RD, Flory CM, Collins FM. 1992. Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol 87: 94-98.
72. Kunnath-Velayudhan S, Salamon H, Wang H-Y, Davidow AL, Molina DM, Huynh VT, Cirillo DM, Michel G, Tal- bot EA, Perkins MD, et al. 2010. Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc Natl Acad Sci 107: 14703-14708.
73. Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, Dockrell H, Pasvol G, Hill AVS. 1998. Human cytolytic and interferon g-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci 95: 270-275.
74. Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS, Ewer K, Hill AVS, Mehta A, Rodrigues C. 2001. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacte-rium tuberculosis infection in healthy urban Indians. J Infect Dis 183: 469-477.
75. Lamonaca V, Missale G, Urbani S, Pilli M, Boni C, Mori C, Sette A, Massari M, Southwood S, Bertoni R, et al. 1999. Conserved hepatitis C virus sequences are highly immu-nogenic for CD4+ T cells: Implications for vaccine development. Hepatology 30: 1088-1098.
76. Lancioni C, Nyendak M, Kiguli S, Zalwango S, Mori T, Mayanja-Kizza H, Balyejusa S, Null M, Baseke J, Mu-lindwa D, et al. 2012. CD8+ T cells provide an immuno-logic signature of tuberculosis in young children. Am J Respir Crit Care Med 185: 206-212.
77. Lazarevic V, Flynn J. 2002. CD8+ T cells in tuberculosis. Am JRespir Crit Care Med 166: 1116-1121.
78. Lewinsohn DM, Alderson MR, Briden AL, Riddell SR, Reed SG, Grabstein KH. 1998. Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J Exp Med 187: 1633-1640.
79. Lewinsohn DM, Zhu L, Madison VJ, Dillon DC, Fling SP, Reed SG, Grabstein KH, Alderson MR. 2001. Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: Definition of antigenic specificity. J Immunol 166: 439-446.
80. Lewinsohn DA, Heinzel AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM. 2003. Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells. Am JRespir Crit Care Med 168: 1346-1352.
81. Lewinsohn DA, Winata E, Swarbrick GM, Tanner KE, Cook MS, Null MD, Cansler ME, Sette A, Sidney J, Lewinsohn DM. 2007. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog 3:1240-1249.
82. Lewinsohn DA, Gold MC, Lewinsohn DM. 2011. Views of immunology: Effector T cells. Immunol Rev 240: 25-39.
83. Lewinsohn DM, Swarbrick GM, Cansler ME, Null MD, Rajaraman V, Frieder MM, Sherman DR, McWeeney S, Lew-insohn DA. 2013. Human CD8 T cell antigens/epitopes identified by a proteomic peptide library. PLoS ONE 8: e67016.
84. Leyten EMS, Lin MY, Franken KLMC, Friggen AH, Prins C, van Meijgaarden KE, Voskuil MI, Weldingh K, Andersen P, Schoolnik GK, et al. 2006. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 8: 2052-2060.
85. Li Y, Zeng J, Shi J, Wang M, Rao M, Xue C, Du Y, He ZG. 2010. A proteome-scale identification of novel antigenic proteins in Mycobacterium tuberculosis toward diagnostic and vaccine development. J Proteome Res 9: 4812-4822.
86. Lindestam Arlehamn CS, Sidney J, Henderson R, Green-baum JA, James EA, Moutaftsi M, Coler R, McKinney DM, Park D, Taplitz R, et al. 2012. Dissecting mechanisms of immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ). J Immunol 188: 5020-5031.
87. Lindestam Arlehamn CS, Gerasimova A, Mele F, Henderson R, Swann J, Greenbaum JA, Kim Y, Sidney J, James EA, Taplitz R, et al. 2013. Memory T cells in latent Mycobac-terium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+ CCR6+ Th1 subset. PLoS Pathog 9: e1003130.
88. Malen H, Berven F, Softeland T, Arntzen M, D'Santos C, De Souza G, Wiker H. 2008. Membrane and membrane-associated proteins in Triton X-114 extracts of Mycobacterium bovis BCG identified using a combination of gel-based and gel-free fractionation strategies. Proteomics 8: 1859-1870.
89. McMurry J, Sbai H, Gennaro ML, Carter EJ, Martin W, De Groot AS. 2005. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinb) 85: 95-105.
90. McMurry JA, Kimball S, Lee JH, Rivera D, Martin W, Weiner DB, Kutzler M, Sherman DR, Kornfeld H, De Groot AS. 2007. Epitope-driven TB vaccine development: A streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr Mol Med 7: 351-368.
91. Mehrotra J, Bishai WR. 2001. Regulation of virulence genes in Mycobacterium tuberculosis. Int J Med Microbiol 291: 171-182.
92. Mohagheghpour N, Gammon D, Kawamura LM, van Vol-lenhoven A, Benike CJ, Engleman EG. 1998. CTL response to Mycobacterium tuberculosis: Identification of an immunogenic epitope in the 19-kDa lipoprotein. J Immunol 161: 2400-2406.
93. Monahan IM, Betts J, Banerjee DK, Butcher PD. 2001. Differential expression of mycobacterial proteins following phagocytosis by macrophages. Microbiology 147: 459-471.
94. Moody DB, Ulrichs T, Muhlecker W, Young DC, Gurcha SS, Grant E, Rosat JP, Brenner MB, Costello CE, Besra GS, et al. 2000. CD1c-mediated T-cell recognition ofisoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404: 884-888.
95. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, Shigeto E, Harada N, Mitarai S, Okada M, et al. 2004. Specific detection of tuberculosis infection: An in-terferon-g-based assay using new antigens. Am J Respir Crit Care Med 170: 59-64.
96. Muller I, Cobbold SP, Waldmann H, Kaufmann SH. 1987. Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun 55: 2037-2041.
97. Mustafa AS, Shaban FA. 2006. ProPred analysis and experimental evaluation of promiscuous T-cell epitopes of three major secreted antigens ofMycobacterium tuberculosis. Tuberculosis 86: 115-124.
98. Mustafa AS, Oftung F, Amoudy HA, Madi NM, Abal AT, Shaban F, Rosen Krands I, Andersen P. 2000. Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines. Clin Infect Dis 30: S201-S205.
99. Mustafa AS, Abal AT, Shaban F, El-Shamy AM, Amoudy HA. 2005. HLA-DR binding prediction and experimental evaluation of T-cell epitopes of mycolyl transferase 85B (Ag85B), a major secreted antigen of Mycobacterium tuberculosis. Med Princ Pract 14: 140-146.
100. Nagai S, Wiker HG, Harboe M, Kinomoto M. 1991. Isolation and partial characterization of major protein antigens in the culture fluid of Mycobacterium tuberculosis. Infect Immun 59: 372-382.
101. North RJ, Jung YJ. 2004. Immunity to tuberculosis. Annu Rev Immunol 22: 599-623.
102. Nyendak MR, Park B, Null MD, Baseke J, Swarbrick G, Mayanja-Kizza H, Nsereko M, Johnson DF, Gitta P, Ok-wera A, et al. 2013. Mycobacterium tuberculosis specific CD8+ T cells rapidly decline with antituberculosis treatment. PLoS ONE 8: e81564.
103. Olsen AW, Hansen PR, Holm A, Andersen P. 2000. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 30: 1724-1732.
104. Orme IM. 1987. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J Immunol 138: 293-298.
105. Orme IM, Collins FM. 1983. Protection against Mycobacte-rium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. J Exp Med 158: 74-83.
106. Orme IM, Collins FM. 1984. Adoptive protection of the Mycobacterium tuberculosis-infected lung. Dissociation between cells that passively transfer protective immunity and those that transfer delayed-type hypersensitivity to tuberculin. Cellular Immunol 84: 113-120.
107. Orme IM, Andersen P, Boom WH. 1993. T cell response to Mycobacterium tuberculosis. J Infect Dis 167: 1481-1497.
108. Oseroff C, Sidney J, Kotturi MF, Kolla R, Alam R, Broide DH, Wasserman SI, Weiskopf D, McKinney DM, Chung JL, et al. 2010. Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J Immunol 185: 943-955.
109. Oseroff C, Sidney J, Tripple V, Grey H, Wood R, Broide DH, Greenbaum J, Kolla R, Peters B, Pomes A, et al. 2012a. Analysis of T cell responses to the major allergens from German cockroach: Epitope specificity and relationship to IgE production. J Immunol 189: 679-688.
110. Oseroff C, Sidney J, Vita R, Tripple V, McKinney DM, South-wood S, Brodie TM, Sallusto F, Grey H, Alam R, et al. 2012b. T cell responses to known allergen proteins are differently polarized and account for a variable fraction of total response to allergen extracts. J Immunol 189:1800-1811.
111. Pal PG, Horwitz MA. 1992. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 60: 4781-4792.
112. Pathan AA, Wilkinson KA, Wilkinson RJ, Latif M, McShane H, Pasvol G, Hill AVS, Lalvani A. 2000. High frequencies of circulating IFN-g-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease. Eur J Immunol 30: 2713-2721.
113. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, Hill AVS, Lalvani A. 2001. Direct ex vivo analysis of antigen-specific IFN-g-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: Associations with clinical disease state and effect oftreat-ment. J Immunol 167: 5217-5225.
114. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV. 1993. Phagocytic processing ofbacterial antigens for class I MHC presentation to T cells. Nature 361: 359-362.
115. Prados-Rosales R, Baena A, Martinez LR, Luque-Garcia J, Kalscheuer R, Veeraraghavan U, Camara C, Nosanchuk JD, Besra GS, Chen B, et al. 2011. Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J Clin Invest 121: 1471-1483.
116. Raviglione MC, Snider DE Jr, Kochi A. 1995. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 273: 220-226.
117. Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy Hanady A, Mustafa Abu S, Jensen Axel K, Holm A, Rosenkrands I, et al. 1999. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 179: 637-645.
118. Reed S, Lobet Y. 2005. Tuberculosis vaccine development; from mouse to man. Microbes Infect 7: 922-931.
119. Rosat JP, Grant EP, Beckman EM, Dascher CC, Sieling PA, Frederique D, Modlin RL, Porcelli SA, Furlong ST, Brenner MB. 1999. CD1-restricted microbial lipid antigen-specific recognition found in the CD8+ a b T cell pool. J Immunol 162: 366-371.
120. Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KLMC, Ottenhoff THM, Klein MR, Huygen K. 2007. Immunogenicity of eight dormancy regulon-encoded proteins ofMycobacterium tuberculosis in DNA-vaccinat-ed and tuberculosis-infected mice. Infect Immun 75: 941-949.
121. Rustad TR, Harrell MI, Liao R, Sherman DR. 2008. The enduring hypoxic pesponse ofMycobacterium tuberculosis. PLoS ONE 3: e1502.
122. Sampson SL. 2011. Mycobacterial PE/PPE proteins at the host-pathogen interface. Clin Dev Immunol 2011: 497-203.
123. Sayes F, Sun L, Di Luca M, Simeone R, Degaiffier N, Fiette L, Esin S, Brosch R, Bottai D, Leclerc C, et al. 2012. Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 Type VII secretion-encoded PE-PPE proteins predicts vaccine potential. Cell Host Microbe 11: 352-363.
124. Schaible UE, Winau F, Sieling PA, Fischer K, Collins HL, Hagens K, Modlin RL, Brinkmann V, Kaufmann SH. 2003. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 9: 1039-1046.
125. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C, et al. 2003. Transcriptional adaptation of Mycobacte-rium tuberculosis within macrophages: Insights into the phagosomal environment. J Exp Med 198: 693-704.
126. Schuck SD, Mueller H, Kunitz F, Neher A, Hoffmann H, Franken KLCM, Repsilber D, Ottenhoff THM, Kauf- mann SHE, Jacobsen M. 2009. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PLoS ONE 4: e5590.
127. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. NEngl J Med 320: 545-550.
128. Sette A, Moutaftsi M, Moyron-Quiroz J, McCausland MM, Davies DH, Johnston RJ, Peters B, Rafii-El-Idrissi Benhnia M, Hoffmann J, Su H-P, et al. 2008. Selective CD4+ T cell help for antibody responses to a large viral pathogen: Deterministic linkage of specificities. Immunity 28: 847-858.
129. Shams H, Barnes PF, Weis SE, Klucar P, Wizel B. 2003. Human CD8+ T cells recognize epitopes of the 28-kDa he-molysin and the 38-kDa antigen ofMycobacterium tuberculosis. J Leukocyte Biol 74: 1008-1014.
130. Shams H, Klucar P, Weis SE, Lalvani A, Moonan PK, Safi H, Wizel B, Ewer K, Nepom GT, Lewinsohn DM, et al. 2004. Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles. J Immunol 173: 1966-1977.
131. Sieling PA, Chatterjee D, Porcelli SA, Prigozy TI, Mazzaccaro RJ, Soriano T, Bloom BR, Brenner MB, Kronenberg M, Brennan PJ, et al. 1995. CD1-restricted T cell recognition of microbial lipoglycan antigens. Science 269: 227-230.
132. Silva CL, Silva MF, Pietro RC, Lowrie DB. 1994. Protection against tuberculosis by passive transfer with T-cell clones recognizing mycobacterial heat-shock protein 65. Immu-nology83: 341-346.
133. Skjot RLV, Agger EM, Andersen P. 2001. Antigen discovery and tuberculosis vaccine development in the post-geno-mic era. Scand J Infect Dis 33: 643-647.
134. Smith SM, Klein MR, Malin AS, Sillah J, Huygen K, Andersen P, McAdam KP, Dockrell HM. 2000. Human CD8+ T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthyBCG-vaccinat-ed controls in The Gambia. InfectImmun 68:7144-7148.
135. Song R, Harding CV. 1996. Roles ofproteasomes, transporter for antigen presentation (TAP), and 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. JImmunol 156: 4182-4190.
136. Sousa AO, Mazzaccaro RJ, Russell RG, Lee FK, Turner OC, Hong S, Van Kaer L, Bloom BR. 2000. Relative contributions ofdistinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc Nat Acad Sci 97: 4204-4208.
137. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, Melian A, Bog-dan C, et al. 1998. An antimicrobial activityofcytolytic T cells mediated by granulysin. Science 282: 121-125.
138. Tang ST, van Meijgaarden KE, Caccamo N, Guggino G, Klein MR, van Weeren P, Kazi F, Stryhn A, Zaigler A, Sahin U, et al. 2011. Genome-based in silico identification of new Mycobacterium tuberculosis antigens activating polyfunctional CD8+ T cells in human tuberculosis. J Immunol 186: 1068-1080.
139. Tangri S, Mothe BR, Eisenbraun J, Sidney J, Southwood S, Briggs K, Zinckgraf J, Bilsel P, Newman M, Chesnut R, et al. 2005. Rationallyengineered therapeutic proteins with reduced immunogenicity. J Immunol 174: 3187-3196.
140. Triccas JA, Gicquel B. 2000. Life on the inside: Probing Mycobacterium tuberculosis gene expression during infection. Immunol Cell Biol 78: 311-317.
141. Ulrichs T, Munk ME, Mollenkopf H, Behr-Perst S, Colangeli R, Gennaro ML, Kaufmann SHE. 1998. Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur J Immunol 28: 3949-3958.
142. van Pinxteren LAH, Ravn P, Agger EM, Pollock J, Andersen P. 2000. Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol 7: 155-160.
143. Vani J, Shaila MS, Chandra NR, Nayak R. 2006. A combined immuno-informatics and structure-based modeling approach for prediction of T cell epitopes of secretory proteins of Mycobacterium tuberculosis. Microbes Infect 8: 738-746.
144. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE. 2009. Emergence of new forms of totally drug-resistant tuberculosis bacilli: Super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136: 420-425.
145. Vordermeier M, Whelan AO, Hewinson RG. 2003. Recognition of mycobacterial epitopes by T cells across mammalian species and use of a program that predicts human HLA-DR binding peptides to predict bovine epitopes. Infect Immun 71: 1980-1987.
146. Vordermeier HM, Hewinson RG, Wilkinson RJ, Wilkinson KA, Gideon HP, Young DB, Sampson SL. 2012. Conserved immune recognition hierarchy of mycobacterial PE/PPE proteins during infection in natural hosts. PLoS ONE 7: e40890.
147. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. 2008. A systematic assessment of MHC Class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 4: e1000048.
148. Weichold FF, Mueller S, Kortsik C, Hitzler WE, Wulf MJ, Hone DM, Sadoff JC, Maeurer MJ. 2007. Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis. Genes Immun 8: 334-343.
149. WHO. 2011. World Health Organization report 2011: Global tuberculosis control. WHO, Geneva.
150. Wilkinson RJ, Wilkinson KA, De Smet KAL, Haslov K, Pas-vol G, Singh M, Svarcova I, Ivanyi J. 1998. Human T-and B-cell reactivity to the 16 kDa a-crystallin protein of Mycobacterium tuberculosis. Scand J Immunol 48: 403-409.
151. Wilson CC, Palmer B, Southwood S, Sidney J, Higashimoto Y, Appella E, Chesnut R, Sette A, Livingston BD. 2001. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus Type 1-derived helper T-lymphocyte epitopes. JVirol 75: 4195-4207.
152. Winslow GM, Cooper A, Reiley W, Chatterjee M, Woodland DL. 2008. Early T-cell responses in tuberculosis immunity. Immunol Rev 225: 284-299.
153. Yewdell JW, Bennink JR. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17: 51-88.
154. Young DB, Gideon HP, Wilkinson RJ. 2009. Eliminating latent tuberculosis. Trends Microbiol 17: 183-188.
155. Yuan Y, Crane DD, Barry CE. 1996. Stationary phase-associated protein expression in Mycobacterium tuberculosis: Function of the mycobacterial a-crystallin homolog. J Bacteriol 178: 4484-4492.
156. Zvi A, Ariel N, Fulkerson J, Sadoff JC, Shafferman A. 2008. Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genomics 1: 18.